The Lonza Group recently launched its Alomune daily immune supplements into the U.S. market, backing the product with clinical trials that show the supplement helps improve the body’s natural defenses for optimized immune health.
More patients with an inflammatory disease of the bowels responded to a drug used for autoimmune disorders than those taking a placebo, according to results of a late-stage clinical trial announced Monday.
British researchers have concluded that a Swiss echinacea extract is both safe and effective in helping to prevent symptoms of the common cold, according to a study published in American Botanical Council's peer-reviewed journal HerbalGram.
A drug under investigation by Teva Pharmaceutical Industries and Active Biotech reduced symptoms and progression of disease in patients with multiple sclerosis, according to results of a late-stage clinical trial.
A recent study gauging the impact of consuming more fish oil showed a marked reduction both in inflammation and in anxiety among a cohort of healthy young people, the Ohio State University Center for Clinical and Translational Science announced Wednesday.
A diabetes drug made by Bristol-Myers Squibb and AstraZeneca significantly reduced Type 2 diabetes patients' blood-sugar levels, compared with placebo, when added to insulin, according to results of a new study.
Patients with gout taking a drug made by Savient Pharmaceuticals experienced "significant" improvements, according to results of two late-stage clinical trials published in the Journal of the American Medical Association.
Soy isoflavone tablets do not appear to be associated with a reduction in bone loss or menopausal symptoms in women within the first five years of menopause, according to a report in the Aug. 8 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Adding an investigational drug for Type 2 diabetes to the common generic drug metformin helped control blood sugar in patients who could not control their blood sugar with metformin alone, according to results of a late-stage clinical study.
A major depressive disorder treatment made by Pfizer significantly reduced the number and severity of moderate-to-severe hot flashes in postmenopausal women, compared with placebo, according to a new study.